drugset
drugset / Trial / NCT02727777

Phase II Study of TAK228 in Relapsed Lymphoma

NCT02727777 ↗

Phase 1/2 Terminated 4 enrolled M.D. Anderson Cancer Center Takeda · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if TAK-228 can help to control relapsed lymphoma. The safety of this drug will also be studied.

Timeline

Start
2017-03-01
Primary completion
2018-07-10
Completion
2018-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Sapanisertib Small molecule 3 mg Oral

Indications

lymphoma